ArticleNature microbiology2026
BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.
Abstract read
In one paragraph
Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
25 authors.
Tomas Raul Wiche SalinasDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8806-4700
Justin HarperDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6948-3501
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3507-0055
Kevin NguyenDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
James AugerDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
Hannah R FloresDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
Sandeep R KaushikDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-3463-3522
Amelia C WilkesDivision of Animal Resources, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
Rachelle L StammenDivision of Animal Resources, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
Jennifer S WoodDivision of Animal Resources, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
Kirk A EasleyDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-4419-2617
Sydney NelsonDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
Gregory K TharpDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3075-755X
Steven E BosingerDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2116-5061
Mackenzie L CottrellDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Emek KoseAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Taina T ImmonenAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-9494-0268
Gregory M LairdAccelevir Diagnostics, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2873-4295
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-2381-1151
R Brad JonesInfectious Diseases Division, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0003-4470-1231
Andrew D BadleyDivision of Infectious Diseases, Mayo Clinic, Rochester, MN, USA.
Guido SilvestriDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.
Deanna A KulpaDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-0411-7295
Mirko PaiardiniDivision of Microbiology and Immunology, Emory National Biomedical Research Center, Emory University, Atlanta, GA, USA. mirko.paiardini@emory.edu.ORCID http://orcid.org/0000-0002-7276-3600
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5MIllumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985kDivision of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) UM1AI164562NIAID NIH HHS P30 AI050409NIAID NIH HHS UM1 AI164562NIH HHS P51 OD011132NIH HHS S10 OD026799NIH HHS U42 OD011023U.S. Department of Health & Human Services | National Institutes of Health (NIH) 75N91019D00024U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI110173U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI83801U.S. Department of Health & Human Services | National Institutes of Health (NIH) ORIP/OD P51OD011132U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30AI050409U.S. Department of Health & Human Services | National Institutes of Health (NIH) P51OD011132U.S. Department of Health & Human Services | National Institutes of Health (NIH) S10 OD026799U.S. Department of Health & Human Services | National Institutes of Health (NIH) U42 PDP11023U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI164562
Abstract
The anti-apoptotic molecule BCL-2 favours the maintenance of the CD4
Identifiers
PMID
42693271What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.